STX.L - Shield Therapeutics plc
| Previous close | 88.50 |
| Open | 89.70 |
| Bid | 85.00 x 0 |
| Ask | 87.00 x 0 |
| Day's range | 85.00 - 89.70 |
| 52-week range | 39.10 - 202.00 |
| Volume | 46,880 |
| Avg. volume | 327,676 |
| Market cap | 99.728M |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | 23.64 |
| EPS (TTM) | 3.60 |
| Earnings date | 07 Aug 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.00 |
- Stockopedia
Two measures that show Shield Therapeutics's positive momentum
Finding stocks that have both positive share price momentum and improving financial health trends is a great way of finding pockets of quality and momentum in8230;
- Simply Wall St.
How Much Did Shield Therapeutics plc's (LON:STX) CEO Pocket Last Year?
Carl Sterritt became the CEO of Shield Therapeutics plc (LON:STX) in 2008. This analysis aims first to contrast CEO...
- Simply Wall St.
Does Shield Therapeutics plc (LON:STX) Have A Particularly Volatile Share Price?
Anyone researching Shield Therapeutics plc (LON:STX) might want to consider the historical volatility of the share...
- Simply Wall St.
Shield Therapeutics plc (LON:STX) Has A ROE Of 11%
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Simply Wall St.
Is Shield Therapeutics plc (LON:STX) Excessively Paying Its CEO?
In 2008 Carl Sterritt was appointed CEO of Shield Therapeutics plc (LON:STX). This analysis aims first to contrast CEO...
- EQS Group
Hardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity
Hardman & Co Research 05-Aug-2019 / 11:22 GMT/BST * * *Hardman & Co: FDA approval opens door to major US opportunityShield Therapeutics (STX) is a commercial-stage pharmaceutical company delivering specialty products that address patients' unmet medical needs, with an initial focus on treating iron deficiency (ID) with Feraccru(R)/Accufer(R). News that the FDA has approved this drug for a broad indication opens it up to a commercial market worth over $1bn. STX has been in discussions with a number of potential partners, but its hand has been strengthened by the regulatory de-risking of Accufer. Its USP will be that oral Accufer is as effective as intravenous iron. The market capitalisation equates to only 4.4x in-market sales.Please click here for the full report:https://www.hardmanandco.com/research/corporate-research/fda-approval-opens-door-to-major-us-opportunity/To contact us:Hardman & Co 35 New Broad Street London EC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCoContacts:Dr Martin HallDr Dorothea HillDr Gregoire Pave +44 20 7194 7622 mh@hardmanandco.com dmh@hardmanandco.com gp@hardmanandco.com Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service
- Simply Wall St.
What Percentage Of Shield Therapeutics plc (LON:STX) Shares Do Insiders Own?
If you want to know who really controls Shield Therapeutics plc (LON:STX), then you'll have to look at the makeup of...
- Simply Wall St.
Does Shield Therapeutics plc (LON:STX) Have A Volatile Share Price?
Anyone researching Shield Therapeutics plc (LON:STX) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility...
